Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 56, Issue 1-6, 1996, Pages 99-105

  Pfeffer, Ulrich ^a   Fecarotta, Emanuela ^a   Arena, Giuseppe ^a   Forlani, Alessandra ^a   Vidali, Giorgio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ALTERNATIVE RNA SPLICING; BREAST; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DELETION MUTANT; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN VARIANT; RNA ANALYSIS; TUMOR CELL;

EID: 0029984401     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(95)00227-8     Document Type: Conference Paper

References (37)

1. Beato M.: Gene regulation by steroid hormones. Cell 56 (1988) 335-334.
2. Parker M. G.: Steroid and related receptors. Curr. Opin. Cell Biol. 5 (1993) 499-504.
3. Tsai M.-J. and O'Malley B. W.: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. A. Rev. Biochem. 63 (1994) 451-486.
4. Evans R. M.: The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895.
5. King R. J. B.: A discussion of the roles of oestrogen and progestin in human mammary carcinogenesis. J. Steroid Biochem. Molec. Biol. 39 (1991) 811-818.
6. Love R. R.: Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J. Clin. Oncol. 7 (1989) 803-815.
7. Clarke R. and Lippman M. E.: Antiestrogen resistance: mechanisms and reversal. In Drug Resistance in Oncology (Edited by B. A. Teicher). Marcel Dekker, New York (1992) pp. 501-536.
8. Esteban J. M., Ahn C., Battifora H. and Felder B.: Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am. J. Clin. Pathol. 102 (1994) 9-12.
9. McPhaul M. J.: Mutations in steroid hormone receptors causing clinical disease. In Steroid Hormone Action (Edited by M. G. Parker). Oxford University Press, Oxford (1993) pp. 186-208.
10. Wang Y. and Miksicek R. J.: Identification of a dominant negative form of the human estrogen receptor. Molec. Endocr. 5 (1991) 1707-1715.
11. McGuire W. L., Chamness G. C. and Fuqua S. A. W.: Abnormal estrogen receptor in clinical breast cancer. J. Steroid Biochem. Molec. Biol. 43 (1992) 243-247.
12. Koehorst S. G., Jacobs H. M., Thijssen J. H. and Blankenstein M. A.: Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF7 breast cancer cells. J. Steroid Biochem. Molec. Biol. 45 (1993) 227-233.
13. Pfeffer U., Fecarotta E., Castagnetta L. and Vidali G.: Estrogen receptor variant messenger RNA lacking exon 4 in estrogen responsive human breast cancer cell lines. Cancer Res. 53 (1993) 741-743.
14. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W. and McGuire W. L.: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51 (1991) 105-109.
15. Miksicel R. J., Lei Y. and Wang Y.: Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res. Treat. 26 (1993) 163-174.
16. Pfeffer U., Fecarotta E. and Vidali G.: Efficient one-tube rt-PCR amplification of rare transcripts using short sequence specific reverse transcription primers. BioTech. 18 (1995) 204-206.
17. Pfeffer U., Fecarotta E. and Vidali G.: Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neo-plastic breast tissues and in MCF-7 cells. Cancer Res. 55 (1995) 2158-2165.
18. Chelly J, Concordet J. P., Kaplan J. C. and Kahn A.: Illegitimate transcription: transcription of any gene in any cell type. Proc. Natn. Acad. Sci. U.S.A. 86 (1989) 2617-2621.
19. Fu X.-D.: Specific commitment of different pre-mRNAs to splicing by single SR proteins. Nature 365 (1993) 82-85.
20. Ponglikitmongkol M., Green S. and Chambon P.: Genomic organization of the human oestrogen receptor gene. EMBO J. 7 (1988) 3385-3388.
21. Lehmann M. J., Hoffmann B. and Pfahl M.: Genomic organization of the retinoic acid gamma gene. Nucl. Acids Res. 19 (1991) 573-577.
22. Daffada A. A. I., Johnston S. R. D., Smith I. E., Detre S., King N. and Dowsett M.: Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 55 (1995) 288-293.
23. Daffada A. A. I., Johnston S. R. D., Nicholls J. and Dowsett M. Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J. Molec. Endocr. 13 (1994) 265-273.
24. Zhang Q. X., Borg A. and Fuqua S. A. W.: An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 53 (1993) 5882-5884.
25. Castles C. G., Fuqua S. A. W., Klotz D. M. and Hill S. M.: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negatives BT-20 human breast cancer cell line. Cancer Res. 53 (1993) 5934-5939.
26. Koehorst S. G. A., Cox J. J., Donker G. H., Lopes da Silva S., Burbach J. P. H., Thijssen J. H. H. and Blankenstein M. A.: Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Molec. Cell. Endocr. 101 (1994) 237-245.
27. Skipper J. K., Youing L. J., Bergeron J. M., Tetzlaff M. T., Osborn C. T. and Crews D.: Identification of an isoform of the estrogen receptor messenger RNA lacking exon four and present in the brain. Proc. Natn. Acad. Sci. U.S.A. 90 (1993) 7172-7175.
28. Dauvois S., Daniellian P. S., White R. and Parker M. G.: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natn. Acad. Sci. U.S.A. 89 (1992) 4037-4041.
29. Chambraud B., Berry M., Redeuilh G., Chambon P. and Baulieu E. E.: Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. J. Biol. Chem. 265 (1990) 20,686-20,691.
30. Fuqua S. A. W., Fitzgerald S. D., Allred C., Elledge R. M., Nafar R. M., McDonnell D. P., O'Malley B. W., Greene G. L. and McGuire W. L.: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 52 (1992) 483-486.
31. Bocquel M. T., Kumar V., Stricker C., Chambon P. and Gronemeyer H.: The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucl. Acids Res. 17 (1989) 2581-2595.
32. Tzukerman M. T., Esty A., Santiso-Mere D., Danelian P., Parker M. G., Stein R. B., Pike J. W. and McDonnell D. P.: Human estrogen receptor transactivational capacity is determined by both cellular and promotor context and mediated by two functionally distinct intramolecular regions. Molec. Endocr. 8 (1994) 21-30.
33. Mader S., Chambon P. and White J. H.: Defining a minimal estrogen receptor DNA binding domain. Nucl. Acids Res. 21 (1993) 1125-1132.
34. Ylikomi T., Bocquel M. T., Berry M., Gronemeyer H. and Chambon P.: Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J. 11 (1992) 3681-3694.
35. Lee J. W., Gulick T. and Moore D. D.: Thyroid hormone receptor dimerization function maps to a conserved subregion of the ligand binding domain. Molec. Endocr. 6 (1992) 1867-1873.
36. Kumar V. and Chambon P.: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156.
37. Kumar V. J., Green S., Stack G., Berry M., Jin J. R. and Chambon P.: Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951.